lorcaserin and Diabetes-Mellitus

lorcaserin has been researched along with Diabetes-Mellitus* in 1 studies

Reviews

1 review(s) available for lorcaserin and Diabetes-Mellitus

Article	Year
APD-356 (Arena). Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:10 Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005. Topics: Animals; Appetite Depressants; Benzazepines; Clinical Trials as Topic; Diabetes Mellitus; Drug Industry; Humans; Hypoglycemic Agents; Obesity; Serotonin 5-HT2 Receptor Agonists; Structure-Activity Relationship; Treatment Outcome	2005

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:10

Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.

Topics: Animals; Appetite Depressants; Benzazepines; Clinical Trials as Topic; Diabetes Mellitus; Drug Industry; Humans; Hypoglycemic Agents; Obesity; Serotonin 5-HT2 Receptor Agonists; Structure-Activity Relationship; Treatment Outcome

2005